← Eichor
Study identifier: NCT06846320 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Condition: Generalized Anxiety Disorder (GAD)  ·  Sponsor: AbbVie

PhasePhase 2
Planned participants315
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

This description comes directly from the study's public registry record.

Talk to the study team

ABBVIE CALL CENTER  ·  844-663-3742  ·  abbvieclinicaltrials@abbvie.com

Always discuss trial participation with your own doctor first.

Locations (52)

University of Alabama - Huntsville Regional Medical Campus /ID# 267818Huntsville, Alabama, United StatesRecruiting
Ima Clinical Research Phoenix (Alea) /ID# 275737Phoenix, Arizona, United StatesRecruiting
Noble Clinical Research /ID# 267952Tucson, Arizona, United StatesCompleted
Advanced Research Center /ID# 267874Anaheim, California, United StatesRecruiting
Axiom Research /ID# 267814Colton, California, United StatesRecruiting
Sun Valley Research Center /ID# 267864Imperial, California, United StatesRecruiting
Synergy San Diego /ID# 267879Lemon Grove, California, United StatesRecruiting
Alliance for Research Alliance for Wellness /ID# 267911Long Beach, California, United StatesRecruiting
NRC Research Institute DTLA /ID# 267832Los Angeles, California, United StatesRecruiting
Excell Research /ID# 267918Oceanside, California, United StatesRecruiting
Inland Psychiatric Medical Group /ID# 268598Temecula, California, United StatesRecruiting
Sunwise Clinical Research /ID# 267863Walnut Creek, California, United StatesRecruiting

+ 40 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06846320